- REGN +0.22%
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?
Yahoo Finance · 11 hours ago
Amgen
Ads
related to: Regeneron PharmaceuticalsLearn about our homegrown technologies and novel approaches to drug discovery. Technology is foundational to our work inventing new medicines.
- Genetic Research
Speeding Drug Discovery
Learn about the RGC
- About Regeneron
Industry-Leading Biotechnology
Reinventing Drug Discovery
- Antibodies at Work
End-to-End Research & Development
See Regeneron's Approved Medicines
- Science & Technology
See Regeneron's New Technology
Turning Science into Medicine
- Genetic Research
Learn How Genmab is Driving the Next Generation of Antibody-Based Medicine. See How Genmab Works to Push Boundaries While Also Driving Sustainability.
Siemens Offers Green Lab Solutions, Biocontainment, Regulatory Compliance and More. Smart Lab Infrastructure Solutions from Siemens. Flexible Spaces for Critical Work.
Learn About Our Efforts to Improve the Lives of Patients, Employees and Our Communities. Stay Current on All Things Vertex and Hear From Leaders on Topics That Matter Most to Us.
Search results
- 1,002.95Add to watchlist+2.16 (+0.22%)At close: Fri. Jun 7, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open999.00High1,006.95Low994.44
- Mkt Cap110.51BP/E (TTM)29.59Div & YieldN/A & N/A
- Prev. Close1,000.7952 Wk. Low684.8152 Wk. High1,016.00
What analysts are sayingTop storiesRelated stocks
22 hours ago · Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...
1 day ago · Learn about Regeneron's financial and operating results, events, and product candidates for serious diseases. Regeneron is a science and technology company that delivers life-transforming medicines for eye, inflammatory, hematologic, pain and infectious diseases.
May 31, 2024 · May 8. Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks. May 6. Regeneron Announces Investor Conference Presentations. May 2. Regeneron Reports First Quarter 2024 Financial and Operating Results. Apr 29.
May 23, 2024 · This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements.
May 31, 2024 · TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on maintenance treatment in certain adult ...
May 20, 2024 · TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking data from the NOTUS Phase 3 trial evaluating the investigational use of Dupixent ® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care ...
May 17, 2024 · TARRYTOWN, N.Y. and WASHINGTON, D.C., Updated as of May 24, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher ...
People also ask
Who is Regeneron Pharmaceuticals Inc?
How does Regeneron Pharmaceuticals make money?
What is Regeneron Pharmaceuticals' Roe?
Does Regeneron Pharmaceuticals pay dividends?
Ads
related to: Regeneron PharmaceuticalsLearn about our homegrown technologies and novel approaches to drug discovery. Technology is foundational to our work inventing new medicines.
Learn How Genmab is Driving the Next Generation of Antibody-Based Medicine. See How Genmab Works to Push Boundaries While Also Driving Sustainability.
Siemens Offers Green Lab Solutions, Biocontainment, Regulatory Compliance and More. Smart Lab Infrastructure Solutions from Siemens. Flexible Spaces for Critical Work.
